Allergy, Asthma, and Inflammation: Which Inflammatory Cell Type Is More Important?

Allergy, Asthma & Clinical Immunology

Solomon O Odemuyiwa¹  Redwan Moqbel² 

[1]Pulmonary Research Group, Department of Medicine, University of Alberta, Edmonton, AB

[2]Department of Immunology, 603 Basic Medical Sciences Building 730 Williams Avenue, University of Manitoba Winnipeg, MB, Canada, R3E OW3

关键词: eosinophilic bronchitis;    mucosal immunity;    smooth muscle cell;    Th2;    Mast cell;    Eosinophil;   

Others  :  1083796
DOI  :  10.1186/1710-1492-4-4-150

【 授权许可】

   
2008 The Canadian Society of Allergy, Asthma and Clinical Immunology

【 参考文献 】

• [1]Bradding P: Allergy Asthma Clin Immunol. 2008, 4:84-90. BioMed Central Full Text
• [2]Brightling CE, Bradding P, Symon FA, et al.: Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002, 346:1699-705.
• [3]Ehrlich P: Ueber die specifischen granulationen des Blutes. Arch Anat Physiol LPZ 1879, 3:571.
• [4]Anthony RM, Rutitzky LI, Urban JF Jr, et al.: Protective immune mechanisms in health infection. Nat Rev Immunol 2007, 7:975-87.
• [5]Tato CM, Laurence A, O'Shea JJ: Helper T cell differentiation enters a new era: le roi est mort; vive le roi! J Exp Med 2006, 203:809-12.
• [6]Butterworth AE, Vadas MA, Wassom DL, et al.: Interactions between human eosinophils and schistosomula of Schistosoma mansoni. II. The mechanism of irreversible eosinophil adherence. J Exp Med 1979, 150:1456-71.
• [7]Butterworth AE, David JR: Eosinophil function. N Engl J Med 1981, 304:154-6.
• [8]Meeusen EN, Balic A, Bowles V: Cells, cytokines and other molecules associated with rejection of gastrointestinal nematode parasites. Vet Immunol Immunopathol 2005, 108:121-5.
• [9]Filley WV, Holley KE, Kephart GM, Gleich GJ: Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet 1982, 2:11-6.
• [10]Frigas E, Gleich GJ: The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol 1986, 77:527-37.
• [11]Moqbel R, Coughlin JJ: Differential secretion of cytokines. Sci STKE 2006, 338:pe26.
• [12]Cieslewicz G, Tomkinson A, Adler A, et al.: The late, but not early, asthmatic response is dependent on IL-5 and correlates with eosinophil infiltration. J Clin Invest 1999, 104:301-8.
• [13]Gleich GJ, Adolphson C: Bronchial hyperreactivity and eosinophil granule proteins. Agents Actions Suppl 1993, 43:223-30.
• [14]Fryer AD, Adamko DJ, Yost BL, Jacoby DB: Effects of inflammatory cells on neuronal M2 muscarinic receptor function in the lung. Life Sci 1999, 64:449-55.
• [15]Fryer AD, Jacoby DB: Function of pulmonary M2 muscarinic receptors in antigen-challenged guinea pigs is restored by heparin and poly-L-glutamate. J Clin Invest 1992, 90:2292-8.
• [16]Fryer AD, Maclagan J: Muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea-pig. Br J Pharmacol 1984, 83:973-8.
• [17]Fryer AD, Stein LH, Nie Z, et al.: Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction. J Clin Invest 2006, 116:228-36.
• [18]Adamko DJ, Yost BL, Gleich GJ, et al.: Ovalbumin sensitization changes the inflammatory response to subsequent parainfluenza infection. Eosinophils mediate airway hyperresponsiveness, m(2) muscarinic receptor dysfunction, and antiviral effects. J Exp Med 1999, 190:1465-78.
• [19]Wardlaw AJ, Moqbel R, Kay AB: Eosinophils: biology and role in disease. Adv Immunol 1995, 60:151-266.
• [20]Clutterbuck E, Shields JG, Gordon J, et al.: Recombinant human interleukin 5 is an eosinophil differentiation factor but has no activity in standard human B cell growth factor assays. Eur J Immunol 1987, 17:1743-50.
• [21]Sanderson CJ: Interleukin-5, eosinophils, and disease. Blood 1992, 79:3101-9.
• [22]Egan RW, Athwahl D, Chou CC, et al.: Pulmonary biology of anti-interleukin 5 antibodies. Mem Inst Oswaldo Cruz 1997, 92(Suppl 2):69-73.
• [23]Kips JC, O'Connor BJ, Langley SJ, et al.: Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 5700, 167:1655-9.
• [24]Leckie MJ, ten Brinke A, Khan J, et al.: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356:2144-8.
• [25]Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS: Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003, 167:199-204.
• [26]Liu LY, Sedgwick JB, Bates ME, et al.: Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. J Immunol 2002, 169:6452-8.
• [27]Liu LY, Sedgwick JB, Bates ME, et al.: Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process. J Immunol 2002, 169:6459-66.
• [28]Nair P, Pizzichini M, Kjarsgaard M, et al.: Abstract in the American Journal of Respiratory and Critical Care Medicine. Am J Respir Crit Care Med 2008, 177:A568.
• [29]Denburg JA: Bone marrow in atopy and asthma: hematopoietic mechanisms in allergic inflammation. Immunol Today 1999, 20:111-3.
• [30]Cameron L, Christodoulopoulos P, Lavigne F, et al.: Evidence for local eosinophil differentiation within allergic nasal mucosa: Inhibition with soluble IL-5 receptor. J Immunol 2000, 164:1538-45.
• [31]Simon HU, Yousefi S, Schranz C, et al.: Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 1997, 158:3902-8.
• [32]Eidelman DH, Minshall E, Dandurand RJ, et al.: Evidence for major basic protein immunoreactivity and interleukin 5 gene activation during the late phase response in explanted airways. Am J Respir Cell Mol Biol 1996, 15:582-9.
• [33]Levi-Schaffer F, Lacy P, Severs NJ, et al.: Association of granulocyte-macrophage colony-stimulating factor (GM-CSF) with the crystalloid granules of human eosinophils. Blood 1995, 85:2579-86.
• [34]Moqbel R, Hamid Q, Ying S, et al.: Expression of mRNA and immunoreactivity for the granulocyte/macrophage colony-stimulating factor (GM-CSF) in activated human eosinophils. J Exp Med 1991, 174:749-52.
• [35]Anwar AR, Moqbel R, Walsh GM, et al.: Adhesion to fibronectin prolongs eosinophil survival. J Exp Med 1993, 177:839-43.
• [36]Justice JP, Borchers MT, Crosby JR, et al.: Ablation of eosinophils leads to a reduction of allergen-induced pulmonary pathology. Am J Physiol Lung Cell Mol Physiol 2003, 284:L169-78.
• [37]Shen HH, Ochkur SI, McGarry MP, et al.: A causative relationship exists between eosinophils and the development of allergic pulmonary pathologies in the mouse. J Immunol 2003, 170:3296-305.
• [38]Lee NA, McGarry MP, Larson KA, et al.: Expression of IL-5 in thymocytes/T cells leads to the development of a massive eosinophilia, extramedullary eosinophilopoiesis, and unique histopathologies. J Immunol 1997, 158:1332-44.
• [39]Foster PS, Hogan SP, Ramsay AJ, et al.: Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 1996, 183:195-201.
• [40]Ochkur SI, Jacobsen EA, Protheroe CA, et al.: Coexpression of IL-5 and eotaxin-2 in mice creates an eosinophil-dependent model of respiratory inflammation with characteristics of severe asthma. J Immunol 2007, 178:7879-89.
• [41]Lee JJ, Dimina D, Macias MP, et al.: Defining a link with asthma in mice congenitally deficient in eosinophils. Science 2004, 305:1773-6.
• [42]Woerly G, Lacy P, Younes AB, et al.: IL-13 release by human eosinophils following CD28-dependent activation. J Leukoc Biol 2002, 72:769-79.
• [43]Schmid-Grendelmeier P, Altznauer F, Fischer B, et al.: Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol 2002, 169:1021-7.
• [44]Wong DT, Weller PF, Galli SJ, et al.: Human eosinophils express transforming growth factor alpha. J Exp Med 1990, 172:673-81.
• [45]Velazquez JR, Lacy P, Mahmudi-Azer S, et al.: Interleukin-4 and RANTES expression in maturing eosinophils derived from human cord blood CD34+ progenitors. Immunology 2000, 101:419-25.
• [46]Phipps S, Ying S, Wangoo A, et al.: The relationship between allergen-induced tissue eosinophilia and markers of repair and remodeling in human atopic skin. J Immunol 2002, 169:4604-12.
• [47]Celestin J, Rotschke O, Falk K, et al.: IL-3 induces B7.2 (CD86) expression and costimulatory activity in human eosinophils. J Immunol 2001, 167:6097-104.
• [48]MacKenzie JR, Mattes J, Dent LA, Foster PS: Eosinophils promote allergic disease of the lung by regulating CD4(+) Th2 lymphocyte function. J Immunol 2001, 167:3146-55.
• [49]Shi HZ, Humbles A, Gerard C, et al.: Lymph node trafficking and antigen presentation by endobronchial eosinophils. J Clin Invest 2000, 105:945-53.
• [50]Matthews AN, Friend DS, Zimmermann N, et al.: Eotaxin is required for the baseline level of tissue eosinophils. Proc Natl Acad Sci USA 1998, 95:6273-8.
• [51]Contreiras EC, Lenzi HL, Meirelles MN, et al.: The equine thymus microenvironment: a morphological and immunohistochemical analysis. Dev Comp Immunol 2004, 28:251-64.
• [52]Throsby M, Herbelin A, Pleau JM, Dardenne M: CD11c+ eosinophils in the murine thymus: developmental regulation and recruitment upon MHC class I-restricted thymocyte deletion. J Immunol 2000, 165:1965-75.
• [53]Lacy P, Moqbel R: Molecular mechanisms in eosinophil activation. Chem Immunol 2000, 76:134-55.
• [54]Gharaee-Kermani M, Phan SH: The role of eosinophils in pulmonary fibrosis. Int J Mol Med 1998, 1:43-53.
• [55]Gorelik L, Flavell RA: Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002, 2:46-53.
• [56]Fallarino F, Grohmann U, Vacca C, et al.: T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002, 9:1069-77.
• [57]Woerly G, Roger N, Loiseau S, et al.: Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin a complexes. J Exp Med 1999, 190:487-95.
• [58]Odemuyiwa SO, Ghahary A, Li Y, et al.: Cutting Edge: Human eosinophils can regulate T-cell subset selection through indoleamine 2, 3-dioxygenase. J Immunol 2004, 173:5909-13.
• [59]Yang D, Rosenberg HF, Chen Q, et al.: Eosinophil-derived neurotoxin (EDN), an antimicrobial protein with chemotactic activities for dendritic cells. Blood 2003, 102:3396-403.
• [60]Yang D, Chen Q, Su SB, et al.: Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J Exp Med 2008, 205:79-90.
• [61]Gleich GJ, Adolphson CR, Leiferman KM: The biology of the eosinophilic leukocyte. Annu Rev Med 1993, 44:85-101.
• [62]Woodruff PG, Khashayar R, Lazarus SC, et al.: Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol 2001, 108:753-8.
• [63]O'Donnell RA, Frew AJ: Is there more than one inflammatory phenotype in asthma? Thorax 2002, 57:566-8.
• [64]Holloway JW, Yang IA, Holgate ST: Interpatient variability in rates of asthma progression: can genetics provide an answer? J Allergy Clin Immunol 2008, 121:573-9.
• [65]Green RH, Brightling CE, McKenna S, et al.: Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002, 360:1715-21.
• [66]Toorn LM, Overbeek SE, de Jongste JC, et al.: Airway inflammation is present during clinical remission of atopic asthma. Am J Respir Crit Care Med 2001, 164:2107-13.
• [67]Pizzichini E, Pizzichini MM, Efthimiadis A, et al.: Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996, 154(2 Pt 1):308-17.
• [68]Jayaram L, Parameswaran K, Sears MR, Hargreave FE: Induced sputum cell counts: their usefulness in clinical practice. Eur Respir J 2000, 16:150-8.
• [69]Mengelers HJ, Maikoe T, Brinkman L, et al.: Immunophenotyping of eosinophils recovered from blood and BAL of allergic asthmatics. Am J Respir Crit Care Med 1994, 149(2 Pt 1):345-51.